Nanalysis Announces First Quarter 2022 Conference Call and Virtual Annual General Meeting

Call at 5:00 p.m. ET TuesdayMay 31stst

General meeting scheduled for June 22n/a to 11:00 a.m. ET

CALGARY, Alta., May 24, 2022 /CNW/ – Nanalysis Scientific Corp. (“the Company”, (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR devices and MRI technology for medical and industrial applications, announces that on Tuesday, May 31, 2022 General director Sean Krakiwski and financial director Luc Caplette will hold a conference call at 5:00 p.m. Eastern Time to discuss the results for the quarter ending March, 31st2022. The Company will file with SEDAR the day before and issue a press release on the day of the call.

Nanalysis Scientific Corp logo. (CNW Group/Nanalysis Scientific Corp.)

Investors interested in participating in the Q1 live call can dial 1-888-664-6392 or 416-764-8659 from overseas. Investors can also access the call online via a listen-only webcast here:, or on the investor relations section of the company’s website HERE.

The webcast will be archived on the Company’s Investor Relations webpage for at least 90 days and a telephone broadcast will be available for seven days following the conference call by calling 1-888-390-0541 or 416-764- 8677, conference ID 991626. .

In light of the public health emergency associated with the Covid-19 pandemic, the Company asks all shareholders to refrain from attending the Annual General Meeting (“AGM”) in person and, at the place, to vote by proxy or by voting instruction form. Investors wishing to attend the AGM virtually can log in using the following numbers: 1-888-664-6392 or 416-764-8659 from abroad. Additionally, the meeting will be webcast using the following link:

On Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada under the symbol “NSCI”, OTC and on the Frankfurt Stock Exchange under the symbol “1N1”. The company’s activity is what we call “MRI and NMR for industry”. The company develops and manufactures portable nuclear magnetic resonance (NMR) spectrometers or analyzers for laboratories and industrial markets. The NMReady-60™ was the first complete portable NMR spectrometer in a single compact enclosure requiring no liquid helium or other cryogens. The company has followed that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis recently announced that it has started selling a 100 MHz device in 2020. The company’s new device will be the most powerful and advanced compact NMR device ever brought to market.

Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharmaceutical, biotechnology, flavors and fragrances, agrochemicals, law enforcement, etc.) as well as in many government and university research laboratories around the world. worldwide. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'(Prime) Technologies Inc. (KPrime), the company maintains a North American sales and service organization of over 40 people that covers scientific instrumentation for pharmaceutical, food, chemical customers and oil and gas, as well as imaging systems for security applications.

In addition, the Company holds a 43% interest in Quad Systems AG (“Quad Systems”), with an option to purchase the remaining shares. Quad Systems is a Zurich-based nuclear magnetic resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice Regarding Forward-Looking Statements and Disclaimers

This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements are often characterized by words such as “expects”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “expects”, ” believes”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will occur”. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results actuals differ materially from those projected in the forward-looking statements. research statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. expressly requires.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.



View original content to download multimedia:

SOURCENanalysis Scientific Corp.



View original content to download multimedia:

Michael P. Boser